BEARINGPOINT
Management and technology consultancy BearingPoint has created a deep dive study on enterprise data resilience . This paper is the first of five companion pieces to the 2021 ‘Can you thrive under pressure’ study, the analysis of over 5,000 projects leading to the ranking of 150 best practice resilient organizations. BearingPoint has also created a resilience benchmarking tool that enables any organization to assess their own alignment with the five fundamental pillars of resilience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220516005860/en/
BearingPoint believe data and analytic resilience is undermined by lack of people empowerment, as 65% of organizations lack data literacy and 56% face cultural resistance to change. Other obstacles impacting data led change initiatives included lack of resources and funding (33%) and disconnect with the business strategy (20%). BearingPoint’s study also concludes that implementation is not easy. The study has found that organizations need a structured vision combined with a disciplined approach e.g., an effective data strategy: without it organizations will fail to generate benefits from investment.
BearingPoint’s research indicates that organizations’ data strategy can only be successful if it is underpinned by the five dimensions of a resilient organization:
1. Understand your data ecosystem: You need the right datapoints to take the right decisions
2. Empower your people for change: Make sure your people interact positively in the data value chain
3. Align data centricity with business outcomes: Steer your data journey so it is agile and focused on business outcomes
4. Use technology to improve agility: Select the architecture that will best support your business model
5. Build proper and effective governance: Data-centricity needs to involve your entire organization, not just leadership
Jan Henderyckx, Partner at BearingPoint asks “is data a hobby or holy grail in your organization? We are witnessing the start of a new industrial revolution, fuelled by data rather than coal. But we believe effective data-centric transformation is not about size, but attitude. Our research shows companies will only survive and thrive if they adopt a rounded, well-balanced and progressive approach across these five dimensions. All are vital. Only by delivering on all of them, your organization will become resilient to change. As all firms, in all sectors must understand that data needs to be at the heart of their business strategy.”
All categories of organization type that BearingPoint studied had room for improvement in the area of data resilience with organizations of all types showing maturing or developing data centricity. BearingPoint observed that Government organizations have lower data resilience scores than privately held and publicly listed companies. According to the study, a reason for this may be that privately held companies may have more scope to execute fast decision making (governance).
Jan Henderyckx will be discussing the study’s finding as the Plenary Keynote speaker at: Creating Data Centric Business Resilience at IRMUK Data Governance Conference Europe, May 18, 2022, in London.
“We are living in a world in which it is increasingly more important to be able to adapt to the changing environment. Your decisions should be based on facts rather than assumptions. Companies that put data centricity at the core of their strategy are going to create value. Especially if they apply a comprehensive approach to all dimensions that impact the implementation of a data strategy,’’ says Jan Henderyckx.
About the study
BearingPoint analyzed over 5,000 client projects, built a model to assess how organizations create successful long-term transformations, and then calibrated resilience profiles based on five observed characteristics. You can download the study here to find out more: https://www.bearingpoint.com/en-gb/insights-events/insights/data-must-be-at-the-heart-of-your-business-strategy/
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
www.bearingpoint.com
www.linkedin.com/company/bearingpoint
@BearingPoint
View source version on businesswire.com: https://www.businesswire.com/news/home/20220516005860/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
